- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05174806
Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients
A Randomized, Open Label, Controlled, Phase 2, Multi-Center Study to Assess Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 (Pravibismane Topical Suspension) in Subjects With Moderate Diabetic Foot Infection (DFI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, open label, controlled, multi-center study. Patients with diabetes mellitus (either type 1 or 2) and an infected wound of the foot with an International Working Group Diabetic Foot (IWGDF) severity rating of moderate will be eligible for the trial after meeting all inclusion criteria and none of the exclusion criteria.
Patients (n = 54) will be randomized in a 2:1 ratio (MBN-101: standard of care). Randomization will be stratified by site.
Patients randomized to the MBN-101 arm will be treated in an outpatient facility 3 times per week for the first 2 weeks. During each of the subsequent 10 weeks, patients will be treated once per week at the outpatient clinic and will be provided with enough MBN-101 for 2 additional days of treatment for self administration at home with or without the assistance of a caregiver. The duration between each dose should be greater than 24 hours, yet not exceed 72 hours for each of the 12 treatment weeks. Patients randomized to the standard of care arm will follow the same schedule (i.e., inclusive of wound dressing changes), though will not be treated with MBN-101.
All subjects will initially receive systemic antibiotic treatment and undergo appropriate sharp debridement at baseline and then as directed by the treating physician through the 12-week treatment period, yet part of the standard of care treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Brett Baker, MSc, DC
- Phone Number: 406-599-1190
- Email: bbaker@microbioncorp.com
Study Contact Backup
- Name: Edmond Lee, BSc
- Phone Number: 604-561-0849
- Email: elee@microbioncorp.com
Study Locations
-
-
California
-
Fresno, California, United States, 93710
- Limb Preservation Platform, Inc.
-
-
Texas
-
Dallas, Texas, United States, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, United States, 75235
- Parkland Comprehensive Wound Center
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center University Wound Care Clinic
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center William P. Clements Jr. University Hospital
-
McAllen, Texas, United States, 78501
- Futuro Clinical Trials, LLC
-
San Antonio, Texas, United States, 78224
- Bio-X-Cell Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.
- Has a skin ulcer located on or distal to the malleolus that is ≥ 4 weeks that is clinically documented, and presents with clinical manifestations of a moderate infection (i.e. erythema extending ≥ 2.0 cm from the wound margin), and not requiring hospitalization.
- Has received no more than 36 hours of antibiotic therapy for the moderately infected ulcer prior to enrollment or there is clinical and/or microbiological evidence of failure of antibiotic treatment for the treatment of the moderately infected ulcer.
- Has documented adequate arterial perfusion in the affected limb by biphasic or triphasic Doppler wave forms, a toe brachial index (TBI) ≥0.75, or an ankle brachial index (ABI) of >0.9).
- Has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained.
Exclusion Criteria:
- Has proven or highly suspected, involvement of bone (i.e., osteomyelitis).
- Has an ulcer due to Charcot arthropathy.
- Has more than one concurrent, infected, diabetic foot wound on the study limb.
- Is unwilling or unable to attend clinic visits and keep research appointments.
- Is unwilling or unable to adhere to the systemic antibiotic treatment prescribed.
- Is unwilling or unable to adhere to proper pressure off-loading of the foot wound (when needed) from enrollment through EOS as directed by the treating physician.
- Has an untreated, uncontrolled, or poorly managed immunosuppressive and or autoimmune disorder.
- Plans to use any topical antibiotics, herbals remedies (e.g., honey), alternative medicines or antimicrobials, either directly or by dressings on their infected DFU at any time from enrollment through the EOS visit.
- Plans to receive treatment with larvae (maggots) for their infected DFU at any time from enrollment through the EOS visit.
- Plans to receive treatment with advanced cellular therapies (e.g., Platelet-derived growth factor (PDGF), Cellular Tissue Products (CTP), granulocyte colony-stimulating factor (G CSF)) for their infected DFU at any time from enrollment through the EOS visit.
- History of major medical noncompliance.
- Any condition that has required treatment with any other bismuth containing compound within 2 weeks prior to enrollment through EOS visit (i.e., Kaopectate or Pepto-Bismol, including topical applications such as Xeroform).
- Plans to receive treatment with Hyperbaric oxygen therapy (HBOT) or topical negative pressure wound therapy (NPWT) for their infected DFU at any time from enrollment through the EOS visit.
- Glycated hemoglobin >12%.
- Has a serum creatinine, ALT, AST or Alkaline Phosphatase >3 times the upper limit of the normal range of the local testing laboratory.
- End stage renal disease requiring dialysis.
- Has an absolute neutrophil count <1000.
- Has participated in an investigational trial to evaluate pharmaceuticals or biologics either concurrently or within the past 30 days.
- Will undergo a planned surgical therapy beyond standard bedside debridement or incision and drainage, to treat the DFI after enrollment.
- Has a known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80)).
- Is immunocompromised and not well-managed due to illness [human immunodeficiency virus (HIV), autoimmune disease] or organ transplant.
- Has a history of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix) unless the subject has been free of cancer for > 5 years.
- Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures.
- Active alcohol abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroin, or methamphetamines) or if drug or alcohol use will interfere with visits in clinic in the opinion of the investigator.
- Has other medical condition(s) which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard of Care
Standard of care treatment without administration of any topical drugs.
|
Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
Other Names:
|
Experimental: Topical Pravibismane (MBN-101)
Topical pravibismane (MBN-101) at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing.
Dosing will occur 3 times per week for the 12 weeks of treatment.
|
Topical Pravibismane
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with adverse events
Time Frame: 12 weeks
|
Safety and tolerability
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects undergoing lower-extremity amputation
Time Frame: 12 weeks
|
Effect of topical pravibismane (MBN-101) suspension on the incidence of lower level extremity amputations
|
12 weeks
|
Proportion of subjects with complete wound closure
Time Frame: 12 weeks
|
Effect of MBN-101 suspension on wound healing
|
12 weeks
|
Proportion of subjects with a clinical cure of infection
Time Frame: 12 weeks
|
Effect of MBN-101 suspension on resolution of infection
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lawrence A Lavery, DPM,MPH, UTSW and Parkland Hospitals, Dallas TX
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MBN-101-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
HealthpointCompleted
Clinical Trials on Topical Pravibismane
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES... and other collaboratorsWithdrawnLeishmaniasis, CutaneousColombia
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruiting
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCutaneous T Cell LymphomaUnited States
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Amazentis SAproDERM GmbHCompleted
-
Amazentis SAproDERM GmbHCompletedErythema | Skin Inflammation | Sun Damaged SkinGermany
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Glia, LLCCompletedContact Lens Discomfort | Contact Lens-induced Corneal Disorder | Contact Lens Acute Red Eye | Contact Lens-induced Corneal Fluorescein StainingUnited States
-
Taro Pharmaceuticals USACompletedScalp PsoriasisUnited States